Adjuvance Technologies Presents Data at the Annual Conference on Vaccinology Research (ACVR)
Pre-clinical data on influenza and COVID-19 demonstrate benefits of TQL-1055
Lincoln, NE–April 28, 2021– Adjuvance Technologies Inc., a privately held biopharmaceutical company developing semi-synthetic saponin adjuvants and vaccines for infectious disease and immuno-oncology, announced the presentation of pre-clinical data at the 2021 Annual Conference on Vaccinology Research (ACVR). Two abstracts were accepted for oral presentation.
“Dose-sparing Potential of the Semisynthetic Saponin Adjuvant TQL1055 for Seasonal and Pandemic Influenza” presents data demonstrating the ability of TQL-1055 to enhance antibody responses to influenza antigens at doses down to 1/128th of the licensed protein dose. “The Semisynthetic Saponin Adjuvant TQL1055 Exhibits Robust Adjuvant Activity and Antigen Dose Sparing Ability During SARS-CoV-2 Spike Protein Vaccination” shows that full-length SARS-CoV-2 spike(S) protein combined with TQL1055 generated high anti-S IgG titers and neutralizing antibodies to the receptor-binding domain of SARS-CoV-2, even at very low antigen doses.
The oral presentations will be available to registered attendees of the ACVR through June 30, 2021 and the slides are available on the Adjuvance website.
About the Annual Conference on Vaccinology Research (ACVR): The ACVR is a well-established forum for exchange of the latest scientific and clinical knowledge in vaccinology. It is sponsored by the National Foundation for Infectious Diseases (NFID), a non-profit organization with the mission of educating the public and healthcare professionals about the burden, causes, prevention, diagnosis and treatment of infectious diseases across the lifespan.
About TQL-1055: TQL-1055 is a rationally designed, semi-synthetic analogue of the saponin adjuvant QS-21. The molecule structure and synthesis are designed for manufacturing efficiency. The natural source material in TQL-1055 that provides the triterpene core is sustainably harvested from the Quillaja saponaria tree. Preclinical evidence indicates that TQL-1055 will have immunostimulatory properties similar to QS-21, with improved tolerability.
About saponin adjuvants: Saponin adjuvants are potent immune stimulators and important components of licensed and clinically-advanced infectious disease vaccines including those against COVID-19, influenza, shingles and malaria. Saponin adjuvants have also been studied in immuno-oncology applications. Existing saponin adjuvants are limited by poor clinical tolerability and inefficient manufacturing requirements. The natural source material in most saponin adjuvants is extracted from the inner lining of the bark of the Quillaja saponaria tree, resulting in a terminal harvest.
About Adjuvance Technologies: Adjuvance Technologies is a privately held biopharmaceutical company dedicated to empowering health through fundamental breakthroughs in vaccine adjuvant design and manufacturing. Adjuvants are critical components that improve the immune response of many vaccines. Adjuvance Technologies has developed the ability to synthesize next-generation saponin adjuvants such as those used in shingles, malaria, flu and COVID-19 vaccines. Its lead adjuvant candidate, TQL-1055, is designed to provide strong immune response and improved tolerability after vaccination. TQL-1055 is in clinical development and multiple indications are being pursued in infectious disease, oncology, neurobiology, substance abuse, and allergy.
Headquartered in Lincoln, Nebraska, Adjuvance is a partner of the Nebraska Innovation Campus. The company has received grant funding from the National Institute of Health (NIH) and closed a Series A investment by Morningside Venture Investments. For more information, visit www.adjuvancetechnologies.com and connect with us on Twitter and LinkedIn.